Project Grant R01CA299939
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $607K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...
- Federal Grant Award Summary Duke University received a $497,972 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on April 1, 2026, with a completion date of March 31, 2031. This research initiative focuses on developing and evaluating EZH2-targeted therapies for advanced prostate cancer, specifically addressing castration-resistant prostate cancer (CRPC). The project involves designing and testing small-molecule EZH2...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $610,459 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. This five-year award supports fundamental research investigating NEUROD1 and cell fate plasticity in olfactory neuroblastoma (ONB), a rare and life-threatening malignancy with limited treatment options. The research employs newly...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. This award funds research focused on therapeutic targeting of SMARCAL1 (SNF2-related CREBBP-activator protein) as a novel treatment strategy for therapy-resistant gliomas, specifically IDH-mutant astrocytomas that have developed...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $402,135 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026 through April 30, 2029. The award funds development of SCHICAR (Single-Cell Hi-C Integrating Chromatin Accessibility and RNA), a novel single-cell tri-modal platform technology that simultaneously captures three-dimensional (3D) genome interactions, chromatin...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $135,993 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025, with completion anticipated by May 31, 2027. The award funds investigative research examining the role of the Abelson (ABL) kinase-regulated hypoxia inducible factor-1 alpha (HIF-1A) and transcriptional co-activator with PDZ-binding motif (TAZ) signaling...
- Federal Project Grant Award Summary Duke University received a $302,524 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded on September 10, 2025, with a completion date of April 30, 2028. This F32 postdoctoral fellowship award supports research investigating the role of SMARCAL1, an annealing helicase protein, in promoting glioma cell proliferation and suppressing tumor-intrinsic inflammation in alternative lengthening of...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of California, Davis a $551,328 Project Grant under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year research initiative focuses on dissecting the role of Carnitine Palmitoyltransferase 1C (CPT1C) in advanced prostate cancer, specifically neuroendocrine prostate cancer (NEPC) that develops following castration-resistant prostate cancer. The...
- Federal Grant Award Summary Duke University received a $411,152 Project Grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded September 5, 2025, with completion targeted for August 31, 2027. The award supports research to identify and validate noncovalent protein interactions of mutant KRAS (MKRAS) inhibitors, specifically examining how four therapeutic compounds—sotorasib, divarasib, MRTX1133, and RMC-6236—interact with proteins beyond their intended...